NCT04318535 - Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

January 13, 2020

Study Completion Date

February 6, 2020

Conditions

Antifungal Agents

Interventions

DRUG

Griseofulvin 500 mg

Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.

DRUG

Griseofulvin 250 mg

Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.

DRUG

Reference Griseofulvin 500 mg

Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.

Trial Locations (1)

GSK Investigational Site, Navi Mumbai